Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 8;17(1):75.
doi: 10.1186/s12936-018-2185-9.

Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape

Affiliations
Review

Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape

Christian Nsanzabana et al. Malar J. .

Abstract

To limit the spread and impact of anti-malarial drug resistance and react accordingly, surveillance systems able to detect and track in real-time its emergence and spread need to be strengthened or in some places established. Currently, surveillance of anti-malarial drug resistance is done by any of three approaches: (1) in vivo studies to assess the efficacy of drugs in patients; (2) in vitro/ex vivo studies to evaluate parasite susceptibility to the drugs; and/or (3) molecular assays to detect validated gene mutations and/or gene copy number changes that are associated with drug resistance. These methods are complementary, as they evaluate different aspects of resistance; however, standardization of methods, especially for in vitro/ex vivo and molecular techniques, is lacking. The World Health Organization has developed a standard protocol for evaluating the efficacy of anti-malarial drugs, which is used by National Malaria Control Programmes to conduct their therapeutic efficacy studies. Regional networks, such as the East African Network for Monitoring Antimalarial Treatment and the Amazon Network for the Surveillance of Antimalarial Drug Resistance, have been set up to strengthen regional capacities for monitoring anti-malarial drug resistance. The Worldwide Antimalarial Resistance Network has been established to collate and provide global spatial and temporal trends information on the efficacy of anti-malarial drugs and resistance. While exchange of information across endemic countries is essential for monitoring anti-malarial resistance, sustainable funding for the surveillance and networking activities remains challenging. The technology landscape for molecular assays is progressing quite rapidly, and easy-to-use and affordable new techniques are becoming available. They also offer the advantage of high throughput analysis from a simple blood spots obtained from a finger prick. New technologies combined with the strengthening of national reference laboratories in malaria-endemic countries through standardized protocols and training plus the availability of a proficiency testing programme, would contribute to the improvement and sustainability of anti-malarial resistance surveillance networks worldwide.

Keywords: Antimalarial; Drug; Landscape; Markers; Molecular; Plasmodium falciparum; Resistance; Surveillance.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Inhibition of CQ-sensitive (3D7) and CQ-resistant (W2) P. falciparum by geldanamycin (GA) and chloroquine (CQ) (Source [72])

References

    1. WHO. Susceptibility of Plasmodium falciparum to antimalarial drugs. Report on global monitoring 1996–2004. Geneva, World Health Organization, 2005. http://www.who.int/malaria/publications/atoz/whohtmmal20051103/en/. Accessed 29 Mar 2017.
    1. WHO. Global report on antimalarial efficacy and drug resistance: 2000–2010. Geneva, World Health Organization, 2010. http://www.who.int/malaria/publications/atoz/9789241500470/en/. Accessed 29 Mar 2017.
    1. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 2008;5:e128. doi: 10.1371/journal.pmed.0050128. - DOI - PMC - PubMed
    1. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14:982–991. doi: 10.1016/S1473-3099(14)70855-2. - DOI - PMC - PubMed
    1. Commons RJ, Thriemer K, Humphreys G, Suay I, Sibley CH, Guerin PJ, et al. The Vivax Surveyor: online mapping database for Plasmodium vivax clinical trials. Int J Parasitol. 2017;7:181–190. - PMC - PubMed

MeSH terms

LinkOut - more resources